

# Giovanni Galati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8586535/publications.pdf>

Version: 2024-02-01

35  
papers

654  
citations

687363

13  
h-index

580821

25  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100248.	4.9	33
2	Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Current Drug Metabolism, 2020, 21, 866-884.	1.2	8
3	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opinion on Drug Safety, 2019, 18, 603-610.	2.4	12
4	Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-9.	1.9	14
5	Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. Journal of Viral Hepatitis, 2018, 25, 1493-1500.	2.0	6
6	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Digestive and Liver Disease, 2018, 50, 1105-1114.	0.9	41
7	Platelet count may impact on lysosomal acid lipase activity determination in dried blood spot. Clinical Biochemistry, 2017, 50, 726-728.	1.9	14
8	Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients. Liver International, 2017, 37, 242-250.	3.9	11
9	Hepatic complications of bariatric surgery : the reverse side of the coin. Acta Gastro-Enterologica Belgica, 2017, 80, 505-513.	1.0	5
10	Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study. Scientific Reports, 2016, 6, 25337.	3.3	41
11	The PNPLA3 rs738409 G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scandinavian Journal of Gastroenterology, 2016, 51, 967-973.	1.5	20
12	Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology. PLoS ONE, 2016, 11, e0156113.	2.5	21
13	Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances. Reviews on Recent Clinical Trials, 2016, 11, 238-252.	0.8	3
14	Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy. World Journal of Hepatology, 2016, 8, 1244.	2.0	6
15	<i>Rhodotorula mucilaginosa</i> skin infection in a patient treated with sorafenib. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1028-1029.	2.4	14
16	Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with <sc>NAFLD</sc>. Liver International, 2015, 35, 569-581.	3.9	73
17	Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World Journal of Gastroenterology, 2015, 21, 7412.	3.3	42
18	Letter to the Editor Haemorrhoidal disease in severe portal hypertension: a combined approach with transjugular intrahepatic portosystemic shunt (TIPS) and transanal haemorrhoidal dearterialization (THD). Archives of Medical Science, 2014, 1, 195-196.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship. <i>Journal of Viral Hepatitis</i> , 2014, 21, e136-7.	2.0	1
20	Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 831-845.	2.4	21
21	Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. <i>BMC Gastroenterology</i> , 2014, 14, 94.	2.0	4
22	Determinants of alanine aminotransferase levels in a large population from Southern Italy: Relationship between alanine aminotransferase and age. <i>Digestive and Liver Disease</i> , 2014, 46, 909-915.	0.9	16
23	Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 2825.	3.3	31
24	Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography. <i>Archives of Medical Science</i> , 2013, 4, 635-639.	0.9	8
25	Distortion-Product Otoacoustic Emissions: A Useful Test for Monitoring Ototoxicity Induced by Pegylated Interferon and Ribavirin Treatment in Patients with Chronic Hepatitis C. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 551-556.	2.1	1
26	A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood'. <i>Aging Clinical and Experimental Research</i> , 2012, 24, 559-60.	2.9	1
27	Angiogenic Cytokines in Patients Undergoing Antiviral Treatment for Chronic Hepatitis C Virus Infection. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 207-210.	1.2	7
28	Deep Vein Thrombosis, Inferior Vena Cava Interruption and Multiple Thrombophilic Gene Mutations. <i>American Journal of the Medical Sciences</i> , 2011, 342, 79-82.	1.1	7
29	Non-cirrhotic portal hypertension with large regenerative nodules: A diagnostic challenge. <i>World Journal of Gastroenterology</i> , 2011, 17, 2580.	3.3	12
30	A mocking finding: portal cavernoma mimicking neoplastic mass: first sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 233-236.	1.6	4
31	Peripheral Graft Infection due to <i>Staphylococcus aureus</i> without Abnormal Findings by 99mTc-HMPAO-Labeled-Leukocyte Scan. <i>Internal Medicine</i> , 2008, 47, 1941-1944.	0.7	0
32	Lower schooling, higher hepatitis C virus prevalence in Italy: An association dependent on age. <i>Journal of Clinical Virology</i> , 2007, 40, 168-170.	3.1	4
33	Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease. <i>Histopathology</i> , 2006, 48, 822-830.	2.9	6
34	Diabetes in chronic liver disease: from old concepts to new evidence. <i>Diabetes/Metabolism Research and Reviews</i> , 2006, 22, 274-283.	4.0	94
35	Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1063-1071.	3.7	48